Literature DB >> 19052222

An autoantibody in narcolepsy disrupts colonic migrating motor complexes.

Michael W Jackson1, Joanne H Reed, Anthony J F Smith, Tom P Gordon.   

Abstract

Despite strong circumstantial evidence for the autoimmune hypothesis of narcolepsy, conventional immunological methods have failed to detect an autoantibody. This study investigated the real-time effects of narcoleptic immunoglobulins on a spontaneous colonic migrating motor complex (CMMC) preparation. IgG from patients with narcolepsy with cataplexy or healthy controls was added directly to isolated mouse colons undergoing CMMC activity to test for autoantibodies that disrupt colonic motility. The effect of immunoglobulins prepared for clinical intravenous treatment (IVIg) on autoantibody-mediated colonic disruption was also assessed. Narcoleptic IgGs markedly reduced the frequency of CMMCs or irreversibly abolished them. Abrogation of CMMCs was followed by an increase in the resting tension of the colon preparation and appearance of atropine-sensitive phasic smooth muscle contractions. IVIg partially neutralized the inhibitory effect of narcoleptic IgG on the CMMCs. The dramatic effect of narcoleptic IgG on CMMC generation is consistent with an autoantibody-mediated disruption of enteric neural pathways. The ex vivo whole-organ approach allows real-time examination of the physiological effects of the narcoleptic autoantibody and offers a new avenue for exploring the autoimmune basis of narcolepsy. The neutralizing effect of IVIg on the autoantibody provides a rationale for the reported clinical improvement in cataplexy when IVIg are given at disease onset.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052222      PMCID: PMC6671602          DOI: 10.1523/JNEUROSCI.4489-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

1.  Furthering the understanding of the pathophysiology of narcolepsy.

Authors:  Michael J Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 2.  Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets.

Authors:  Estelle T Spear; Gary M Mawe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-10-11       Impact factor: 4.052

3.  Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients.

Authors:  Vesna Cvetkovic-Lopes; Laurence Bayer; Stéphane Dorsaz; Stéphanie Maret; Sylvain Pradervand; Yves Dauvilliers; Michel Lecendreux; Gert-Jan Lammers; Claire E H M Donjacour; Renaud A Du Pasquier; Corinne Pfister; Brice Petit; Hyun Hor; Michel Mühlethaler; Mehdi Tafti
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

4.  IgG abnormality in narcolepsy and idiopathic hypersomnia.

Authors:  Susumu Tanaka; Makoto Honda
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

5.  Increased immune complexes of hypocretin autoantibodies in narcolepsy.

Authors:  Aude Deloumeau; Sophie Bayard; Quentin Coquerel; Pierre Déchelotte; Christine Bole-Feysot; Bertrand Carlander; Valérie Cochen De Cock; Sergueï O Fetissov; Yves Dauvilliers
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

6.  Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset.

Authors:  Adi Aran; Ling Lin; Sona Nevsimalova; Giuseppe Plazzi; Seung Chul Hong; Karin Weiner; Jamie Zeitzer; Emmanuel Mignot
Journal:  Sleep       Date:  2009-08       Impact factor: 5.849

7.  Narcolepsy: a review.

Authors:  Gbolagade Sunmaila Akintomide; Hugh Rickards
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-08       Impact factor: 2.570

8.  Narcolepsy after A/H1N1 vaccination.

Authors:  Mirian Fabiola Studart Gurgel Mendes; Dirceu de Campos Valladares Neto; Rosângela Aparecida de Azevedo; Paulo Caramelli
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 9.  History of narcolepsy at Stanford University.

Authors:  Emmanuel J M Mignot
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.